Serpin B3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer

Gordon Urquhart, Keith M. Kerr, Marianne Nicolson, Peh Sun Loo, Ravi Sharma, Raj Shrimali, Russell D. Petty (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    INTRODUCTION: In a previous biomarker discovery project using gene-expression profiling we identified Serpin B3 (SB3) as a predictor of resistance to platinum doublet chemotherapy (PtC) in non-small-cell lung cancer (NSCLC). This independent prospective study was designed to confirm the predictive utility of SB3.

    METHODS: SB3 immunohistochemistry was scored by previously validated criteria (score 0 = negative, score 1 = 1%-10% tumor cells positive, score 2 = 11%-50% tumor cells positive, and score 3 = >50% tumor cell positive) in 197 patients with stage IV NSCLC treated with PtC. This provided 80% power to detect a median survival increase from 150 days in patients with an SB3 immunohistochemistry score of 2 or more to 300 days in those with an SB3 score of 0 or 1.

    RESULTS: Thirty-six percent of NSCLCs stained positive for SB3. Median survival for SB3 negative/score 0 was 332 days, SB3 positive/score 1 was 268 days, and SB3 positive/score 2 or 3 was 120 days (p = 0.004). Cox proportional hazards analysis demonstrated that SB3 positivity is an independent predictor of survival (hazard ratio = 1.87; 95% confidence interval, 1.29-2.71; p = 0.001).The disease control rate in SB3 score 0, 1 = 65%, and score of 2 or more = 20 % (p = 0.002), with median survival 306 days (score 0, 1) versus 120 days (score ≥ 2, hazard ratio= 1.71; 95% confidence interval. 1.14-3.10; p = 0.002).

    CONCLUSIONS: SB3-positive immunohistochemistry score of 2 or more (>10% tumor cells positive) identifies a subgroup of patients with stage IV NSCLC who have a poor survival (median 120 days) when treated with PtC, similar to that estimated for untreated or chemo-refractory stage IV NSCLC. Further prospective qualification using biospecimens from randomized studies is needed, but SB3 seems to be a useful biomarker that identifies a highly resistant subgroup in whom PtC should be avoided.

    Original languageEnglish
    Pages (from-to)1502-1509
    Number of pages8
    JournalJournal of Thoracic Oncology
    Volume8
    Issue number12
    DOIs
    Publication statusPublished - Dec 2013

    Keywords

    • Adenocarcinoma
    • Adult
    • Aged
    • Antigens, Neoplasm
    • Antineoplastic Combined Chemotherapy Protocols
    • Carcinoma, Large Cell
    • Carcinoma, Non-Small-Cell Lung
    • Carcinoma, Squamous Cell
    • Female
    • Follow-Up Studies
    • Humans
    • Immunoenzyme Techniques
    • Lung Neoplasms
    • Male
    • Middle Aged
    • Neoplasm Staging
    • Prognosis
    • Prospective Studies
    • Serpins
    • Survival Rate
    • Tumor Markers, Biological

    Fingerprint Dive into the research topics of 'Serpin B3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this